Talbot 2002

1 Treatments

**Studied treatment** intermittent oral capecitabine (1255 mg m\(^{-2}\) twice daily, days 1-14, (22 patients))

**Control treatment** i.v. paclitaxel (175 mg m\(^{-2}\)),

Concomittant treatments  -

2 Patients

**Patients** patients with metastatic/advanced breast cancer pretreated with anthracyclines

Inclusion criteria  -

Exclusion criteria  -

3 Methods

Blinding  -

Design  -

Centers  -

Geographical area  -

Sizes -9/-9

4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
</table>

5 References